Consequences of persistent HBV infection in HIV: The double-edged sword of nucleos(t)ide analogs

Future Virology

Volumn 7, Issue 2, 2012, Pages 139-148

  Boyd, Anders ^a   Girard, Pierre Marie ^a   Lacombe, Karine ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

adefovir; B virus; entecavir; genetic variability; hepatitis; human immunodeficiency virus; lamivudine; mutations; resistance; telbivudine; tenofovir; treatment response

Indexed keywords

DNA; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; NUCLEOTIDE DERIVATIVE;

ALLELE; ANTIVIRAL THERAPY; ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DNA REPLICATION; DRUG RESISTANCE; GENETIC VARIABILITY; GENOME; HEPATITIS B; HEPATITIS B VIRUS; HLA SYSTEM; HLA TYPING; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; LIVER CELL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL;

CERCOPITHECINE HERPESVIRUS 1; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84856889373     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.144     Document Type: Article

References (88)

1. Benhamou Y, Katlama C, Lunel F et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 125(9), 705-712 (1996). (Pubitemid 126450357)
2. Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 46(4), 562-568 (2000). (Pubitemid 30305823)
3. Benhamou Y, Bochet M, Thibault V et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30(5), 1302-1306 (1999). (Pubitemid 29510871)
4. Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int. 31(Suppl. 1), 111-116 (2011).
5. Woo G, Tomlinson G, Nishikawa Y et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139(4), 1218-1229 (2010).
6. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137(5), 1593-1608.E1-E2 (2009).
7. Zoutendijk R, Reijnders JG, Brown A et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 54(2), 443-451 (2011).
8. Snow-Lampart A, Chappell B, Curtis M et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 53(3), 763-773 (2011).
9. Lacombe K, Gozlan J, Boyd A et al. Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV- HBV-coinfected patients. Antivir. Ther. 13(5), 705-713 (2008).
10. Peters MG, Andersen J, Lynch P et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 44(5), 1110-1116 (2006). (Pubitemid 44748362)
11. Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology 48(4), 1062-1069 (2008).
12. McMahon MA, Jilek BL, Brennan TP et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N. Engl. J. Med. 356(25), 2614-2621 (2007). (Pubitemid 46961006)
13. Ratcliffe L, Beadsworth MB, Pennell A, Phillips M, Vilar FJ. Managing hepatitis B/ HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 25(8), 1051-1056 (2011).
14. Lacombe K, Gozlan J, Boyd A et al. Hepatitis B virus blippers and rebounders under treatment with tenofovir in HIV-hepatitis B virus co-infection. Presented at: 16thConference on Retroviruses and Opportunistic Infections. Montréal, QC, Canada, 8-11 February 2009.
15. de Vries-Sluijs TE, Reijnders JG, Hansen BE et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 139(6), 1934-1941 (2010).
16. Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 359(23), 2442-2455 (2008).
17. Wiegand J, Wedemeyer H, Finger A et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir. Ther. 13(4), 547-554 (2008). (Pubitemid 352016717)
18. Heathcote EJ, Marcellin P, Buti M et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1), 132-143 (2011).
19. Lee JM, Ahn SH, Kim HS et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology 53(5), 1486-1493 (2011).
20. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, Katlama C. Six-year follow-up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV-HBV-coinfected patients. Antivir. Ther. 16(2), 199-205 (2011).
21. Boyd A, Lacombe K, Maylin S et al. HBs antigen quantification as a marker of HBs and HBe antigens loss in HIV/HBV co-infected patients treated with tenofovir. Presented at: 17th Conference on Retrovirus and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
22. Psevdos G Jr, Kim JH, Suh JS, Sharp VL. Predictors of loss of hepatitis B surface antigen in HIV-infected patients. World J. Gastroenterol. 16(9), 1093-1096 (2010).
23. Piroth L, Pol S, Lacombe K et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J. Hepatol. 53(6), 1006-1012 (2010).
24. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 21(6), 771-774 (2007). (Pubitemid 46568638)
25. Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect. Dis. 11, 178 (2011).
26. Manesis EK, Papatheodoridis GV, Tiniakos DG et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J. Hepatol. 55(1), 61-68 (2011).
27. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir. Ther. 11(7), 909-916 (2006). (Pubitemid 44736182)
28. Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128(7), 1890-1897 (2005). (Pubitemid 40824700)
29. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126(7), 1750-1758 (2004). (Pubitemid 38736340)
30. Volz T, Lutgehetmann M, Wachtler P et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133(3), 843-852 (2007). (Pubitemid 47374140)
31. Iser DM, Warner N, Revill PA et al. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J. Virol. 84(12), 5860-5867 (2010).
32. Iser DM, Avihingsanon A, Wisedopas N et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 25(2), 197-205 (2011).
33. Lacombe K, Massari V, Girard PM et al. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 20(3), 419-427 (2006).
34. Bourne EJ, Dienstag JL, Lopez VA et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J. Viral Hepat. 14(1), 55-63 (2007). (Pubitemid 46012362)
35. Lutgehetmann M, Volzt T, Quaas A et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir. Ther. 13(1), 57-66 (2008). (Pubitemid 351541674)
36. Coffin CS, Mulrooney-Cousins PM, Peters MG et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J. Viral Hepat. 18(6), 415-423 (2011).
37. Coffin CS, Mulrooney-Cousins PM, van Marle G, Roberts JP, Michalak TI, Terrault NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl. 17(8), 955-962 (2011).
38. Lohr HF, Krug S, Herr W et al. Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B. Liver 18(6), 405-413 (1998). (Pubitemid 28550325)
39. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J. Hepatol. 39(4), 595-605 (2003). (Pubitemid 37204661)
40. Chen Y, Li X, Ye B et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res. 91(1), 23-31 (2011).
41. + T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infection. J. Hepatol. 43(1), 45-52 (2005). (Pubitemid 40812351)
42. Lv G, Ying L, Ma WJ et al. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virol. J. 7, 207 (2010).
43. Stoop JN, van der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41(4), 771-778 (2005). (Pubitemid 40462939)
44. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 5(11), E13869 (2010).
45. + T cells following antiviral treatment of chronic hepatitis B. Antimicrob. Agents Chemother. 55(2), 888-894 (2011).
46. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J. Hepatol. 52(4), 616-619 (2010).
47. Boni C, Fisicaro P, Valdatta C et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J. Virol. 81(8), 4215-4225 (2007). (Pubitemid 46586915)
48. Lopes AR, Kellam P, Das A et al. Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection. J. Clin. Invest. 118(5), 1835-1845 (2008). (Pubitemid 351632386)
49. Fisicaro P, Valdatta C, Massari M et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2), 682-693, 693.E1-693.E4 (2010).
50. Evans A, Riva A, Cooksley H et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion. Hepatology 48(3), 759-769 (2008).
51. Schurich A, Khanna P, Lopes AR et al. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 53(5), 1494-1503 (2011).
52. Chang JJ, Sirivichayakul S, Avihingsanon A et al. Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection. J. Virol. 83(15), 7649-7658 (2009).
53. Lascar RM, Lopes AR, Gilson RJ et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J. Infect. Dis. 191(7), 1169-1179 (2005). (Pubitemid 40404377)
54. Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/ HBV coinfection. J. Infect. Dis. 188(12), 1815-1819 (2003). (Pubitemid 38064865)
55. + T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J. Virol. 79(5), 3038-3051 (2005). (Pubitemid 40270583)
56. + T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J. Virol. 84(6), 2657-2665 (2010).
57. Lichtfuss GF, Hoy J, Rajasuriar R, Kramski M, Crowe SM, Lewin SR. Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection. Biomark. Med. 5(2), 171-186 (2011).
58. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006). (Pubitemid 44435155)
59. + T cells leads to reversible immune dysfunction. Nat. Med. 12(10), 1198-1202 (2006). (Pubitemid 44527357)
60. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8(11), 1246-1254 (2007). (Pubitemid 350011764)
61. Jones RB, Ndhlovu LC, Barbour JD et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J. Exp. Med. 205(12), 2763-2779 (2008).
62. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am. J. Pathol. 163(6), 2441-2449 (2003). (Pubitemid 37466485)
63. Bohne F, Chmielewski M, Ebert G et al. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 134(1), 239-247 (2008). (Pubitemid 350309333)
64. Lin CL, Tsai SL, Lee TH, Chien RN, Liao SK, Liaw YF. High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B. Gut 54(1), 152-161 (2005).
65. Svicher V, Trignetti M, Gori C et al. HIV-Driven Immunosuppression Regulates HBV Evolution in HBV/HIV-co-infected Patients. Presented at: 16th Conference on Retrovirus and Opportunistic Infections. Montréal, QC, Canada, 8-11 February 2009.
66. Yang PL, Althage A, Chung J et al. Immune effectors required for hepatitis B virus clearance. Proc. Natl Acad. Sci. USA 107(2), 798-802 (2010).
67. Oliviero B, Cerino A, Varchetta S et al. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections. J. Hepatol. 55(1), 53-60 (2011).
68. Jiang Y, Ma Z, Xin G et al. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010, 143026 (2010).
69. Lazdina U, Alheim M, Nystrom J et al. Priming of cytotoxic T cell responses to exogenous hepatitis B virus core antigen is B cell dependent. J. Gen. Virol. 84(Pt 1), 139-146 (2003). (Pubitemid 36113559)
70. Wu C, Liu Y, Zhao Q et al. Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: a preliminary approach for anti-HBV immunotherapy. Virol. J. 7(1), 370 (2010).
71. Launay O, van der Vliet D, Rosenberg AR et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults withHIV-1: a randomized controlled trial. JAMA 305(14), 1432-1440 (2011).
72. Tuaillon E, Tabaa YA, Baillat V, Petitjean G, Reynes J, Vendrell JP. Long-term persistence of memory B cells specific for hepatitis B surface antigen in HIV-1-infected patients. AIDS 21(17), 2343-2345 (2007). (Pubitemid 350287462)
73. del Pozo Balado Mdel M, Leal M, Mendez Lagares G et al. Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine. J. Infect. Dis. 202(3), 362-369 (2010).
74. Moir S, Ho J, Malaspina A et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J. Exp. Med. 205(8), 1797-1805 (2008).
75. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir. Ther. 15(3 Pt B), 471-475 (2010).
76. Torresi J, Earnest-Silveira L, Civitico G et al. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the fingers subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. Virology 299(1), 88-99 (2002). (Pubitemid 35007514)
77. Lacombe K, Boyd A, Lavocat F et al. Treament-induced and vaccine escape HBV mutants in HIV-HBV co-infected patients: a longitudinal analysis. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 30 October-3 November 2009.
78. Ueda Y, Marusawa H, Egawa H et al. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir. Ther. 16(4), 479-487 (2011).
79. Protzer-Knolle U, Naumann U, Bartenschlager R et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology 27(1), 254-263 (1998).
80. Homs M, Jardi R, Buti M et al. HBV core region variability: effect of antiviral treatments on main epitopic regions. Antivir. Ther. 16(1), 37-49 (2011).
81. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J. Exp. Med. 193(3), 297-305 (2001). (Pubitemid 32524513)
82. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51(3), 581-592 (2009).
83. Pollicino T, Belloni L, Raffa G et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130(3), 823-837 (2006). (Pubitemid 43374531)
84. Wang L, Wu XP, Zhang W et al. Evaluation of genetic susceptibility loci for chronic hepatitis B in Chinese: two independent case-control studies. PLoS One 6(3), E17608 (2011).
85. Guo X, Zhang Y, Li J et al. Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology 53(2), 422-428 (2011).
86. Mbarek H, Ochi H, Urabe Y et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum. Mol. Genet. 20(19), 3884-3892 (2011).
87. Kamatani Y, Wattanapokayakit S, Ochi H et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat. Genet. 41(5), 591-595 (2009).
88. Thomas RL, Apps R, Qi Y et al. Effect of HLA-DP cell surface expression on hepatitis B virus pathogenesis. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 27 February-2 March 2011.